You are here: Home » Reuters » News
Business Standard

Teva rebuffs EU pay-for-delay charge at hearing

Reuters  |  BRUSSELS 

BRUSSELS (Reuters) - Israeli drugmaker Teva rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug at a hearing on Tuesday.The European Commission charged the company with the pay-for-delay drug deal in July last year, after hitting Denmark's Lundbeck , U.S. giant Johnson & Johnson and French drugmaker Servier over similar practices in recent years."Teva has responded to the statement of objections robustly, and has attended the oral hearing today," the company said in a statement, referring ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Wed, March 14 2018. 00:47 IST